Q2 revenue doubles and profit rises, but operating cash flow stays negative

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionNegative Operating CashflowResults View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹25.22

prior close

₹26.36

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.8%+3.7% vs sector

On the reaction day the stock moved 3.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

+0.0

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9pendingpending-0.8+3.7

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anlon Healthcare approved unaudited results for the quarter and six months ended 30 September 2026. Consolidated revenue rose 102% to Rs 10,560.97 lakh in Q2 and 126% to Rs 19,317.24 lakh for the half year. Profit after tax rose 84% to Rs 1,717.80 lakh in Q2 and 98% to Rs 2,545.94 lakh for the half year. The consolidated EBITDA margin narrowed to about 24% from 26%, while half-year operating cash flow was negative Rs 794.25 lakh.

Likely market impact

Strong revenue and profit growth is positive, but weaker margins and negative operating cash flow may limit gains in the stock.